Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Pediatrics*

Manuscript NO: 85151

Title: Safety and Efficacy of Intravitreal Anti Vascular Endothelial Growth Factor for Severe Posterior Retinopathy of Prematurity with Flat Fibrovascular Proliferation

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06351861
Position: Peer Reviewer
Academic degree: PhD

Professional title: Assistant Professor

Reviewer's Country/Territory: United States

Author's Country/Territory: India

Manuscript submission date: 2023-05-05

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-06-15 14:40

Reviewer performed review: 2023-06-15 15:29

Review time: 1 Hour

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [Y] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [ ] Grade B: Good [Y] Grade C: Fair [ ] Grade D: No novelty
Creativity or innovation of this manuscript	[ ] Grade A: Excellent [ ] Grade B: Good [Y] Grade C: Fair [ ] Grade D: No creativity or innovation

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	[ ] Grade A: Excellent [ ] Grade B: Good [Y] Grade C: Fair [ ] Grade D: No scientific significance
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [Y] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous
	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This prospective study evaluated the structural outcomes of IVA injection in the treatment of severe posterior ROP with significant FVP and the author concluded that when the IVA injection is given prior to 37 weeks PMA, while disease is in phase 2, it is less likely to cause contracture of pre-existing FVP. Questions/suggestions for the authors. 1. The criteria for choosing between the two different drugs, 0.625 mg of bevacizumab or 0.2 mg of ranibizumab, need to be indicated. It looks like the majority of eyes received 0.625 mg of bevacizumab as the authors stated “Thirty two eyes (89%) received 0.625 mg of intravitreal bevacizumab and 4 eyes (11%) received 0.2 mg of intravitreal ranibizumab (0.2mg)”. 2. Were both drugs injected once? Why would some patients need additional dose of anti-vascular endothelial growth factor (VEGF)? What was the additional drug? 3. It would help the readers tremendously if the authors could clearly present their results in tables.

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Pediatrics*

Manuscript NO: 85151

Title: Safety and Efficacy of Intravitreal Anti Vascular Endothelial Growth Factor for Severe Posterior Retinopathy of Prematurity with Flat Fibrovascular Proliferation

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06432649
Position: Peer Reviewer
Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Thailand

Author's Country/Territory: India

Manuscript submission date: 2023-05-05

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-05-12 01:25

Reviewer performed review: 2023-06-15 20:56

Review time: 34 Days and 19 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [ ] Grade B: Good [Y] Grade C: Fair [ ] Grade D: No novelty
Creativity or innovation of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No creativity or innovation

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No scientific significance
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [Y] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous
	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

There is no benefit to obtain new knowledge from this study but the result would lead to suggestion for a big data collection from registration or multi-center observation study.Please recheck grammar and typing errors.